Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 387Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × atamestane × Clear all
NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Completed
865 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00010322 2014-03-26

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
Breast

Breast Neoplasms

NCT00267553 2007-09-10

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
200 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
842 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡